Home > Node > Subnode Activatable Theranostics Huang, P. Current Medicinal Chemistry 26(8): 13102019ISSN/ISBN: 0929-8673 PMID: 31189459 Document Number: 697913 Document emailed within 1 workday Purchase for $29.90 Secure & encrypted paymentsRelated DocumentsDel Vecchio, S.; Zannetti, A.; Fonti, R.; Pace, L.; Salvatore, M. 2007: Nuclear imaging in cancer theranostics Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology and Section of the Society Of. 51(2): 152-163Yue, X.; Dai, Z. 2018: Liposomal Nanotechnology for Cancer Theranostics Current Medicinal Chemistry 25(12): 1397-1408Brouwers, G-Jan.; Leebeek, F.W.G.; Tanck, M.W.T.; Wouter Jukema, J.; Kluft, C.; de Maat, M.P.M. 2003: Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris Thrombosis and Haemostasis 90(1): 92-100Jovan P. Antovic 2003: Thrombin Activatable Fibrinolysis Inhibitor (TAFI) A Link between Coagulationand Fibrinolysis Clinical Laboratory 49(9-10): 475-486